Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell ...

In lab studies, the orally active drug has been shown to degrade the VAV1 protein expressed in T- and B- cells. VAV1 is thought to be a signalling protein involved in the production of pro ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

MRT-6160 degrades a protein called VAV1. "Overall, we see this favorable collaboration agreement as additional robust validation of Monte Rosa's (platform) as well as acknowledgement of the ...

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.

Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and ...